This phase III trial is investigating the safety and effectiveness of two types of targeted therapy in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS).
This trial is treating patients with acute myeloid leukaemia or myelodysplastic syndrome.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A placebo controlled study to compare ivosidenib or enasidenib in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome
Other Non-Commercial Sponsor
Eligible patients will receive up to two cycles of induction therapy, up to three cycles of consolidation therapy and maintenance treatment. Across the three treatments, patients will be randomly selected to receive a placebo (no treatment) or oral Enasidenib or Ivosidenaib once a day for the whole induction cycle, until the end of consolidation and for up to two years maintenance.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More